Mint Pharmaceuticals Announces Strategic Partnership
Mint Pharmaceuticals Inc. is thrilled to share its recent partnership with Bayer Canada to distribute ADALAT® XL® (nifedipine extended-release tablets) 30 mg tablets in the Canadian market. This collaboration marks a significant achievement in ensuring that essential medications are readily available to healthcare professionals and patients across the nation.
Overview of ADALAT® XL®
ADALAT® XL® has been an integral part of the Canadian healthcare landscape since it first received market authorization in 1995. This medication plays a crucial role in managing chronic stable angina and treating mild to moderate essential hypertension. With this partnership, both Mint and Bayer aim to enhance its accessibility and availability, reinforcing their dedication to patient care.
Comments from Leadership
"Canadian patients and healthcare professionals depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint," expressed Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals. He emphasized that this partnership with Bayer strengthens their commitment to quality and reliability, ensuring Canadians receive the support they need with ADALAT® XL®.
Benefits of the Partnership
"We are excited to partner with Mint Pharmaceuticals Inc., a company recognized for its commitment to quality and customer care," said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. This alliance allows Bayer to leverage Mint's extensive distribution network, ensuring the ongoing availability of ADALAT® XL® for those in need.
Commitment to Quality and Accessibility
Both companies share a core value in providing high-quality pharmaceutical products and maintaining exceptional service. The collaboration will focus on high standards of distribution to ensure that healthcare professionals and patients can rely on the constant availability of ADALAT® XL®.
About Mint Pharmaceuticals
Mint Pharmaceuticals stands as a notable Canadian-owned manufacturer of high-quality and affordable generic medicines. Over the past decade, Mint has developed one of the most robust pharmaceutical supply chains in Canada, helping to avert numerous national drug shortages across essential medicines. Recently, Mint launched its 100th molecule, celebrating significant growth in its portfolio.
Recognized by Deloitte as one of Canada's Best Managed Companies for seven consecutive years, Mint also achieved Platinum Club status in 2025, underscoring its excellence in the industry. The company is proud to be a member of the Canadian Generic Pharmaceutical Association (CGPA).
About Bayer
Bayer is a global enterprise with a commitment to improving healthcare and nutrition. Their mission, "Health for all, Hunger for none," drives them to provide innovative products and services that support both people and the planet. In the fiscal year 2024, Bayer employed around 93,000 people and generated substantial revenue from its operations, emphasizing its market position and dedication to sustainable development.
Frequently Asked Questions
What is the purpose of the partnership between Mint Pharmaceuticals and Bayer?
The partnership is focused on the distribution of ADALAT® XL® in Canada, enhancing access to this essential medication for patients.
What conditions does ADALAT® XL® treat?
ADALAT® XL® is indicated for the management of chronic stable angina and for treating mild to moderate essential hypertension.
How does Mint Pharmaceuticals contribute to patient care?
Mint Pharmaceuticals is committed to ensuring the availability of vital medicines through a robust supply chain and a focus on quality.
What milestones has Mint Pharmaceuticals achieved recently?
Mint recently launched its 100th molecule in Canada and has received recognition as one of Canada’s Best Managed Companies.
What is Bayer’s mission statement?
Bayer's mission is "Health for all, Hunger for none," highlighting their commitment to improving the quality of life through their products and services.
